Test Price
5,000 AED✅ Home Collection Available
Combined Whole Exome Sequencing (WES) & Chromosomal Microarray (CMA) – UAE | 5,000 AED | DHA Licensed
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139). Dual‑platform confirmation for all pathogenic variants.
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily 8 AM–11 PM (sample transport at 2–8 °C). For patients within Dubai Healthcare City, hospital‑grade home collection is included.
- ✓ Clinical Guidance: Complimentary telephonic post‑test guidance by a DHA‑licensed genetic counsellor to interpret findings and plan next steps.
- ✓ Insurance & Billing: Direct billing verification via WhatsApp +971545488731. Pre‑approval support for major UAE insurers.
Test Overview & Methodology
This combined analysis integrates Whole Exome Sequencing (WES) and Chromosomal Microarray (CMA) to detect single‑nucleotide variants, indels, and copy‑number changes in a single workflow. It offers the highest diagnostic yield for paediatric neurodevelopmental delay, dysmorphic syndromes, and hereditary cancer predisposition. The test is processed at DNA Labs UAE, Dubai Healthcare City, using Illumina NovaSeq for exome capture and Affymetrix CytoScan HD Array for genome‑wide CNV detection.
| Parameter | Our Combined WES + CMA | WES Only (Closest Alternative) |
|---|---|---|
| Methodology | NGS (Illumina NovaSeq) Exome Capture + Affymetrix CytoScan HD Array | NGS Exome Capture only |
| Resolution | Single‑nucleotide variants, indels, CNVs ≥25 kb, AOH regions | SNVs/indels; limited CNV detection |
| Diagnostic Yield (Neurodevelopmental) | ~45–50% | ~30–35% |
| Turnaround Time | 14–21 days | 14–21 days |
| Clinical Utility in UAE | DHA‑recommended for global developmental delay, multiple congenital anomalies, cancer predisposition | Mainly for suspected monogenic disorders |
Physician Insight & Safety Protocols
— Ms. Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Information
Medication & Clinical Considerations
- Do not discontinue or adjust any prescribed medication without explicit instruction from your treating physician. Genetic results may have implications for certain therapies, but changes must be supervised by your specialist.
- Inform your genetic counsellor of any recent blood transfusions or allogeneic bone marrow transplants – these may interfere with germline DNA results.
Exclusion Criteria & Emergency Red Flags
Safety Exclusion Criteria & Emergency Red Flags
- This test is not a substitute for acute medical evaluation; if the patient has sudden neurological deterioration, seizures, or loss of consciousness, proceed to the nearest emergency room immediately.
- Combined WES + CMA is intended solely for germline (constitutional) genetic analysis. It must not be used for somatic tumour profiling or minimal residual disease monitoring.
- Do not order for low‑risk population screening without pre‑ and post‑test genetic counselling.
Patient FAQ & Clinical Guidance
1. What is the key difference between whole exome sequencing and chromosomal microarray, and why are they combined?
Whole exome sequencing reads the protein‑coding regions of all ~20,000 genes to detect small genetic spelling mistakes, while microarray scans the entire genome for large deletions or duplications. Combining both catches almost every clinically relevant genetic change in a single test, maximising diagnostic yield.
2. Does the test require any special preparation before sample collection?
No fasting or medication adjustment is needed. However, please inform the nursing team if you are taking any blood‑thinning medications or have had a recent blood transfusion to ensure sample quality.
3. How long until I receive the combined report, and who will explain the results?
The final integrated report is typically ready within 14 to 21 calendar days. A DHA‑licensed genetic counsellor will schedule a complimentary teleconsultation to walk you through every finding.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance
This diagnostic service complies with:
• Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – all genetic data are stored on encrypted servers within the UAE.
• Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
• Federal Decree‑Law No. 4 of 2016 on Medical Liability – ensuring patient safety and informed consent.
Laboratory ISO 9001:2015 Certified – Cert: INT/EGQ/2509DA/3139.
DHA Facility License No: 1143.
Clinical & Logistical Metadata
| Test Name | Combined Whole Exome Sequencing (WES) & Chromosomal Microarray (CMA) |
| Price (AED) | 5,000 AED |
| Turnaround Time | 14–21 calendar days |
| Sample Type / Matrix | Peripheral whole blood (EDTA) – 3–5 mL; VIP Mobile Phlebotomy & Cold‑Chain Home Collection available |
| Methodology Used | NGS (Illumina NovaSeq) Exome Capture + Affymetrix CytoScan HD Array |
| ICD-10-CM Code | Z13.79, Q99.9, Z15.09 |
| LOINC Code | 81247‑2 – Genetic variant analysis panel |
| DHA Facility License & Laboratory Address | DHA License No: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate Lab Branding: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians